OR WAIT null SECS
June 29, 2024
This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.
June 28, 2024
Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.
June 21, 2024
The transaction, announced June 20, follows Bora’s purchase of Minnesota-based Upsher-Smith Laboratories earlier in 2024.
June 11, 2024
Syntegon will expand its processing and packaging by acquiring the Spanish equipment supplier.
May 30, 2024
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
May 24, 2024
With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.
May 17, 2024
Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.
May 06, 2024
The request for more information was received weeks after an application to the FTC was refiled to approve the deal.
May 03, 2024
Cormica’s first US Acquisition is intended to support to organic growth of TPM laboratories.
The loan is intended to support Ennogen’s growth as it looks to international acquisitions.